Thapsigargin (TG), by inducing perturbations in cellular Ca 2+ homeostasis, can induce apoptosis, but the molecular mechanisms remain to be fully elucidated. We have recently reported that TG-induced apoptosis appears to involve the DR5-dependent apoptotic pathway that cross talks with the mitochondrial pathway via TG-induced Bid cleavage. In this study, we have utilized Bax-proficient and -deficient HCT116 human colon cancer cells to investigate the effect of Bax deficiency on TG-induced apoptosis and TG regulation of the DR5 and mitochondrial pathways. Our results indicate that Bax-deficient cells are less sensitive to undergo apoptosis following TG treatment. Our results further demonstrate that TG-induced apoptosis is coupled with DR5 upregulation and caspases 8 and 3 activation, as well as Bid cleavage in both Bax-proficient and -deficient cells, although caspase 3 activation was reduced in Bax-deficient cells. TG also promoted the release of cytochrome c into cytosol and caspase 9 activation in Bax-proficient cells but not in Bax-deficient cells. These findings suggest that although Bax is not absolutely required for death receptor (DR)-dependent signals, it appears to be a key molecule in TGregulated mitochondrial events. Bax-deficient cells were relatively more resistant to Apo2L/TRAIL than the Baxproficient counterparts. However, the combination of Apo2L/TRAIL and TG was more effective in mediating apoptosis in both Bax-proficient and -deficient cells and that was coupled with activation of caspases 8 and 3. Although both agents in combination also induced cytochrome c release into cytosol and caspase 9 activation in Bax-proficient cells, these events were abrogated in Bax-deficient cells. Our results thus suggest that the combination of Apo2L/TRAIL and TG appears to bypass the Bax deficiency-induced defects in the mitochondrial (intrinsic) pathway by engaging the DR5-dependent apoptotic signals (extrinsic pathway).
A wealth of information suggests that perturbations in cellular Ca 2+ homeostasis can induce apoptosis (Furuya et al., 1994; Krebs, 1998; Nutt et al., 2002a; Kim et al., 2002; Tombal et al., 2002) , but the molecular mechanisms remain to be fully elucidated. Evidence suggests that Bcl-2 family members such as Bcl-2, Bclx L and Bax are important modulators of apoptosis that involves alterations in intracellular Ca 2+ homeostasis (Nutt et al., 2002a; Kim et al., 2002) . For example, Bcl-2 is believed to control the endoplasmic reticulum (ER) and mitochondrial Ca 2+ homeostasis as well as the release of cytochrome c from mitochondria into cytosol (Murphy et al., 1996; Shimizu et al., 1998; Foyouzi-Youssefi et al., 2000; Kim et al., 2002) . Bcl-2 has been reported to associate with mitochondrial and ER membranes via its carboxyl-terminal transmembrane domain (Yang and Korsmeyer, 1996) . Several lines of evidence suggest that the proapoptotic Bax appears to play an essential role in apoptosis that occurs as a consequence of perturbations in cellular Ca 2+ homeostasis (Nutt et al., 2002a, b) . For example, Bax, normally a cytosolic protein, translocates to mitochondria in response to apoptotic signals that affect Ca 2+ homeostasis Hsu et al., 1997; Nechushtan et al., 1999; Boya et al., 2002; Nutt et al., 2002a,b) . Bax translocation to mitochondria is believed to induce the release of cytochrome c into cytosol and subsequent activation of caspase 9 and apoptosis (Shimizu et al., 1999) .
Thapsigargin (TG), a sesquiterpene lactone, is known to perturb Ca 2+ homeostasis by inhibiting the ER Ca
2+
ATPases (Sagara and Inesi, 1991) . TG-induced inhibition of ER Ca 2+ ATPases blocks the reuptake of cytosolic Ca 2+ into the ER, which results in the increased levels of cytoplasmic Ca 2+ and depletion of Ca 2+ within the ER (Sagara and Inesi, 1991) . Previous evidence suggested that TG can induce apoptosis by engaging the mitochondrial pathway (Wertz and Dixit, 2000) . We have recently demonstrated that TG can also activate the death receptor 5 (DR5) pathway by increasing the expression of DR5 at the mRNA and protein levels (He et al., 2002a) . We further reported the existence of a potential cross talk between TG-activated DR5 and mitochondrial pathways via TG-induced Bid cleavage (He et al., 2002a) . Since Bax is believed to play an important role in response to apoptotic signals that affect Ca 2+ homeostasis, we therefore, undertook this study to investigate the effect of Bax deficiency on the DR5 and mitochondrial pathways during TG-induced apoptosis.
We utilized Bax-proficient (Bax +/À ) and Bax-deficient (Bax À/À ) HCT116 human colon cancer cells (Zhang et al., 2000) . The Bax-deficient cells do not express Bax protein because of targeted deletion of both alleles (Figure 1) . The results presented in Figure 2 indicate that although Bax deficiency did not completely abolish TG-induced apoptosis, the Bax-deficient cells were clearly less sensitive to TG-induced apoptosis than the Baxproficient counterparts. These results suggest that although TG-mediated apoptosis appears to involve both the Bax-dependent and -independent pathways, Bax obviously plays an important role in TG-induced apoptosis.
We also investigated the effect of Bax deficiency on TGinduced DR5 expression. As shown in Figure 3 , TG upregulated the DR5 mRNA expression in both the Bax-proficient and -deficient cells. TG also upregulated the DR5 protein levels in both Bax-proficient and -deficient cells (data not shown). These results suggest that although Bax deficiency confers relative resistance to TG, it does not affect this agent's ability to modulate DR5 expression.
Next, we explored the effect of TG on the intracellular apoptotic molecules that are engaged by the DR (extrinsic) and mitochondrial (intrinsic) pathways in Bax-proficient and -deficient cells. As shown in ; to detect the cleaved fragments of caspase 9, the autoradiographs were exposed for a longer time, and thus the duration of exposure showing procaspase 9 is different from that one showing the cleaved fragments). Since caspase 9 also activates caspase 3, these results may explain why there was a reduced activation of caspase 3 by TG in Bax-deficient cells (Figure 4a , lane 4). Cytochrome c release from mitochondria into cytosol and its interactions with procaspase 9 are important events in the activation of caspase 9 (reviewed by Wang, 2001 ). Since TG did not induce caspase 9 activation in Bax-deficient cells, it was of interest to investigate its effect on cytochrome c release into cytosol. We, therefore, analysed the cytosolic fractions from untreated and TG-treated cells. As shown in Figure 4b , TG clearly induced the release of cytochrome c into cytosol in Bax-proficient cells but not in Bax-deficient cells. These results thus suggest that the absence of TG-induced Bax deficiency and thapsigargin-induced apoptosis Q He et al caspase 9 activation in Bax-deficient cells could be because of the lack of cytochrome c release from mitochondria into cytosol. Together these results suggest that TG appears to engage both the extrinsic and intrinsic pathways to mediate apoptosis, and although Bax is not absolutely required for DR-dependent signals, it appears to be a key mediator of TG-induced apoptotic signals that engage the mitochondrial and postmitochondrial events.
Apo2L/TRAIL is a DR5 ligand that appears to be a promising novel anticancer agent (Walczak et al., 1999; Ashkenazi et al., 1999; Jin et al., 2002) . Since TG upregulated DR5 expression in both Bax -proficient and -deficient cells (Figure 3) , it was of interest to investigate whether the use of Apo2L/TRAIL in combination with TG would further enhance DR5-mediated apoptotic signaling and consequently overcome Bax deficiency. We have previously reported that TG upregulation of DR5 precedes TG-induced apoptosis and can be noted within 4 h (He et al., 2002a) . We have recently reported that Apo2L/TRAIL (50 ng/ml) can efficiently induce apoptosis within 7 h in Bax-proficient cells, whereas the Bax-deficient cells are less sensitive (He et al., 2002b) . We, therefore, selected a 7 h time point to treat these cells with Apo2L/TRAIL and/or TG. As shown in Figure 5 , Bax-proficient cells were clearly more sensitive to undergo apoptosis in response to Apo2L/TRAIL treatment than their Bax-deficient counterparts ( Figure 5 ). Furthermore, Apo2L/TRAIL and TG in combination were more effective in inducing apoptosis in both Bax-proficient and -deficient cells ( Figure 5 ).
We also explored the effects of Apo2L/TRAIL plus TG on the intracellular apoptotic molecules that are engaged by extrinsic and intrinsic pathways in Bax-proficient and -deficient cells. As shown in Figure 6a , TG alone for 7 h had a minimal effect on procaspases 8, 3 and 9 or Bid in Bax-proficient (Figure 6a, lane 3) or Bax-deficient cells (Figure 6a , Cytosolic fractions were prepared as we have recently described (He et al., 2002b) and Western blotting was performed using a monoclonal anticytochrome c antibody (PharMingen). The same blot was later probed with anti-b-actin antibody to demonstrate comparable loading in each lane Figure 5 Apo2L/TRAIL and TG interact to mediate apoptosis in Bax-proficient and -deficient cells. Bax-proficient (Bax +/À ) or Baxdeficient (Bax À/À ) cells were either left untreated or treated with TG (50 nm), Apo2L/TRAIL (50 ng/ml) or the combination of TG and Apo2L/TRAIL for approximately 7 h. Cells were processed for apoptosis detection by counting floating and adherent cells using a phase contrast microscope as reported previously (He et al., 2002b) . Values are the means of two independent experiments; bars, s.e.m.
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Q He et al lane 7), indicating that short-term treatment with TG had yet to affect the extrinsic and intrinsic pathways of apoptosis. Apo2L/TRAIL, when used alone for 7 h, clearly induced caspases 8, 3 and 9 activation as well as Bid cleavage in Bax-proficient cells ( Figure 6a , lane 2). Apo2L/TRAIL also induced caspases 8 and 3 activation as well as Bid cleavage in Bax-deficient cells, although the effect was less pronounced (Figure 6a , lane 6). Apo2L/TRAIL-induced caspase 9 activation, however, was clearly abrogated in Bax-deficient cells (Figure 6a , lane 6). These results were in line with those shown in Figure 5 , which indicate that Apo2L/TRAIL-induced apoptosis in Bax-deficient cells was also less pronounced than that noted in Bax-proficient counterparts. Apo2L/ TRAIL and TG in combination effectively induced caspases 8 and 3 activation as well as Bid cleavage in both Bax-proficient and -deficient cells (Figure 6a , compare lanes 4 and 8). Although Apo2L/TRAIL and TG in combination also induced caspase 9 activation in Bax-proficient cells, their effect on caspase 9 was abrogated in Bax-deficient cells (Figure 6a , compare lanes 4 and 8).
We also investigated whether, under these experimental conditions, cytochrome c was released from mitochondria into cytosol. Towards this end, we prepared the cytosolic fractions from untreated, Apo2L/TRAIL, TG, and Apo2L/TRAIL+TG-treated Bax-proficient and -deficient cells. Analyses of cytosolic fractions revealed that Apo2L/TRAIL either alone or in combination with TG promoted the release of cytochrome c into cytosol in Bax-proficient cells (Figure 6b , lanes 2 and 4) but not in Bax-deficient cells (Figure 6b , lanes 6 and 8). Based on these findings, it is reasonable to suggest that the absence of caspase 9 activation in Bax-deficient cells in response to Apo2L/TRAIL or Apo2L/TRAIL+TG treatment could result because of the lack of cytochrome c release into cytosol. Taken together, these results suggest that (i) TG-induced apoptosis involves extrinsic and intrinsic pathways of apoptosis and (ii) although TG-induced apoptosis and activation of mitochondrial events are compromised in Bax-deficient cells, enhanced activation of DR5-dependent signals by Apo2L/TRAIL in combination with TG appears to bypass these defects.
In this study, we have investigated the effect of Bax deficiency on the DR5 and mitochondrial pathways during TG-induced apoptosis. We have utilized Bax-proficient and -deficient HCT116 human colon cancer cells, and our results indicated that the Baxdeficient cells were less sensitive to TG-induced apoptosis than the Bax-proficient counterparts. We have also found that TG upregulated DR5 expression in both Bax-proficient and -deficient cells and that TG-induced DR5 expression was associated with caspases 8 and 3 activation and Bid cleavage (Figures 3 and 4) . Thus, although Bax deficiency was associated with relative TG resistance, it did not considerably affect the ability of TG to regulate DR5 and its downstream signaling molecules.
Activation of caspase 9 is a postmitochondrial event that occurs in response to apoptotic signals that engage the mitochondria (reviewed by Wang, 2001 ). Cytochrome c release from mitochondria into cytosol and its interactions with procaspase 9 are important events that lead to caspase 9 activation (reviewed by Wang, 2001 ). Our results indicated that TG promoted the release of cytochrome c from mitochondria into cytosol that was coupled with activation of caspase 9 in Bax-proficient cells. Bax deficiency, however, clearly abrogated the TGinduced cytochrome c release from mitochondria into cytosol as well as caspase 9 activation. These findings thus highlight the fact that Bax appears to be a key molecule via which TG engages the mitochondrial pathway.
Our results further indicate that although TG-induced caspase 8 activation and Bid cleavage were about comparable in both Bax-proficient and -deficient cells, TG-induced caspase 3 activation was blunted in Since TG-induced cytochrome c release into cytosol and caspase 9 activation are also abrogated because of Baxdeficiency, it appears likely that TG-induced caspase 3 activation involves signals from both the extrinsic and intrinsic pathways. Based on our results, it is reasonable to suggest that (i) although Bax deficiency does not significantly affect TG-induced activation of DR-dependent events such as caspase 8 activation and Bid cleavage, (ii) the ability of truncated Bid to cross talk with the mitochondria to induce cytochrome c release and promote caspase 9 activation may be compromised. In the absence of caspase 9 activation, caspase 3 is not fully activated and that may result in reduced TGinduced apoptosis in Bax-deficient cells. In this context, it is of note that TG induced Bid cleavage in Baxdeficient cells yet cytochrome c was not released into cytosol (Figure 4a, b) . Mikhailov et al. (2003) have recently reported that Bax or Bak oligomerization occurs independent of Bid cleavage. Using Bax-deficient BMK and HCT116 cells, they found that Bax was absolutely required for cytochrome c release into cytosol following hypoxia-induced apoptosis (Mikhailov et al., 2003) . It is not clear whether this is a general phenomenon, but this appears to be the case during TG-induced apoptosis in Bax-deficient HCT116 cells.
We also investigated the interactions between Apo2L/ TRAIL and TG in activating the DR5 and mitochondrial pathways in Bax-proficient and -deficient cells. We and others have recently reported that Bax-deficient cells are less sensitive to undergo Apo2L/TRAIL-induced apoptosis than the Bax-proficient counterparts (Burns and El-Deiry 2001; Deng et al., 2002; He et al., 2002b; LeBlanc et al., 2002) . Our present results indicate that the combination of Apo2L/TRAIL and TG was more effective in mediating apoptosis in both Bax-proficient and -deficient cells. The combination of Apo2L/TRAIL and TG promoted the activation of caspases 8 and 3 as well as mitochondrial pathway (cytochrome c release and caspase 9 activation) in Bax-proficient cells. Both agents in combination were also more effective in activating caspases 8 and 3 in Bax-deficient cells. In Bax-deficient cells, however, the combination of TG and Apo2L/TRAIL did not promote cytochrome c release and caspase 9 activation. Our results thus suggest that the combination of Apo2L/TRAIL and TG by engaging the DR5-dependent apoptotic signals (extrinsic pathway) appears to bypass the Bax deficiency-induced defects in the mitochondrial (intrinsic) pathway.
A large body of recent evidence suggests that dysregulation of apoptosis appears to underlie malignant progression (reviewed by Johnstone et al., 2002) . Defects in apoptosis regulation are believed to confer upon cancer cells a growth advantage on the one hand and resistance to anticancer agents on the other (reviewed by Nicholson, 2000; Johnstone et al., 2002; Reed, 2002) . A full understanding of the molecular mechanisms by which tumor cells acquire resistance to apoptosis is expected to help in developing novel anticancer strategies. In this regard, our present findings indicate that Bax is a key player in mediating apoptosis in response to agents that perturb cellular Ca 2+ homeostasis. Our results also indicate that Apo2L/TRAIL requires Bax to efficiently mediate apoptosis. Bax mutations have been reported in various malignancies (Zhang et al., 2000 and references therein) . Mutational inactivation of Bax in cancer cells is predicted to confer resistance against anticancer agents particularly those that utilize mechanisms similar to that used by TG. Apo2L/TRAIL has shown significant promise as a novel agent for cancer therapy since it selectively targets cancer cells with little systemic toxicity in animals (Walczak et al., 1999; Ashkenazi et al., 1999) . Efforts are currently underway to test the efficacy of Apo2L/TRAIL as an anticancer agent in clinical trials. Based on our findings, it is reasonable to predict that tumors harboring inactive Bax are likely to be less sensitive to Apo2L/TRAIL. Thus, the therapeutic potential of Apo2L/TRAIL in such tumors could be enhanced by combining Apo2L/TRAIL with other agents that upregulate the death receptor(s) of this novel ligand.
In conclusion, we have demonstrated that TG, an agent that perturbs cellular Ca 2+ homeostasis, engages the extrinsic and intrinsic pathways and requires Bax to execute apoptosis fully. Although TG does not absolutely require Bax to engage the extrinsic pathway, Bax deficiency abrogates TG-induced activation of the intrinsic pathway. TG upregulates DR5 and the combination of the DR5 ligand Apo2L/TRAIL and TG appears to bypass the Bax deficiency-induced defects in the intrinsic pathway by fully engaging the DR5-dependent apoptotic signals.
